<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04714502</url>
  </required_header>
  <id_info>
    <org_study_id>AAMBI2</org_study_id>
    <nct_id>NCT04714502</nct_id>
  </id_info>
  <brief_title>Asphyxia Associated Metabolite Biomarker Investigation 2</brief_title>
  <acronym>AAMBI2</acronym>
  <official_title>Verification of Biomarkers to Examine Neonatal Asphyxia-induced Hypoxic-ischemic Encephalopathy Study on Neuro-developmental Follow-up at 2 Years A Prospective Multicenter Observational Study for Development of a Diagnostic Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InfanDx AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cukurova University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Children's Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>InfanDx AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Follow-up of participants of AAMBI1 study at age of at least 2 years.&#xD;
      AAMBI1(ClinicalTrials.gov ID: NCT03354208): Verification of biomarkers in a human population&#xD;
      for their ability to diagnose the severity of neonatal asphyxia. These biomarkers linked to&#xD;
      asphyxia have been identified in animal studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Follow-Up on neuro-developmental status of Study participants of AAMBI1.&#xD;
      AAMBI1(ClinicalTrials.gov ID: NCT03354208): The aim of the study is to verify the application&#xD;
      of combinations of several laboratory parameters in early postnatal blood samples, for&#xD;
      identification of infants, who will suffer from early abnormal neonatal neurological outcome,&#xD;
      in a population at risk. The population at risk is defined as term and late preterm (&gt;36&#xD;
      weeks of gestation) human infants following perinatal hypoxia-ischemia with or without&#xD;
      postnatal resuscitation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">October 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Participants with normal neuro-developmental status</measure>
    <time_frame>up to 42 month age</time_frame>
    <description>All infants with normal neuro-developmental status</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants with potentially abnormal neuro-developmental status</measure>
    <time_frame>up to 42 month age</time_frame>
    <description>All infants who do not fulfill outcomes 1, 3 or 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants with abnormal neuro-developmental status - HIE</measure>
    <time_frame>up to 42 month age</time_frame>
    <description>Presence of adverse 2 years neuro-developmental outcome likely attributable to perinatal hypoxic-ischemic brain injury</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants with abnormal neuro-developmental status - non-HIE</measure>
    <time_frame>up to 42 month age</time_frame>
    <description>Presence of adverse 2 years neuro-developmental Outcome not attributable to perinatal hypoxic-ischemic brain injury</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">144</enrollment>
  <condition>Birth Asphyxia</condition>
  <arm_group>
    <arm_group_label>Infants enrolled in AAMBI1</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Children, who had been enrolled in the AAMBI study immediately after birth because they had&#xD;
        been suspected to be at risk for perinatal brain injury (hypoxic-ischemic encephalopathy,&#xD;
        HIE) and/or evaluated for hypothermia therapy or because they had been enrolled in AAMBI as&#xD;
        healthy controls (with adaptation disorder only).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infants previously enrolled in the AAMBI1 study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Missing valid written informed parental consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Months</minimum_age>
    <maximum_age>48 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ron Meyer</last_name>
    <role>Study Director</role>
    <affiliation>InfanDx AG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Turkey Cukurova University</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Firat</name>
      <address>
        <city>Elazığ</city>
        <zip>23110</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Özel Güngören Hastanesi</name>
      <address>
        <city>Istanbul</city>
        <zip>34164</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mersin University School of Medicine</name>
      <address>
        <city>Mersin</city>
        <zip>33343</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biomarkers</keyword>
  <keyword>asphyxia</keyword>
  <keyword>Hypoxic ischemic encephalopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
    <mesh_term>Asphyxia Neonatorum</mesh_term>
    <mesh_term>Asphyxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

